Formulary and medical drug changes coming Jan. 1, 2027 for commercial group, individual and Medicare members
Beginning Jan. 1, 2027, several medical and formulary drug coverage changes will take effect for commercial group, individual and Medicare members
Diabetes drug Rybelsus® discontinued, to be replaced by Ozempic® tablets
Rybelsus®, a medication used to treat type 2 diabetes, is being discontinued by the manufacturer and replaced with Ozempic® tablets.
Reminder: Medicare Bridge prior authorization requests aren’t processed through Priority Health
Reminder: Medicare Bridge prior authorization requests aren’t processed through Priority Health
We're encouraging select members to discuss biosimilars with their providers
We're encouraging select members to discuss biosimilars with their providers
New CMS program expands Medicare access to GLP-1 weight loss medications starting July 1
New CMS BRIDGE program expands Medicare access to GLP-1 weight loss medications starting July 1
Drug changes coming July 1 for commercial group and individual members
Drug changes coming July 1 for commercial group and individual members.
Upcoming medical and pharmacy drug changes
Upcoming medical and pharmacy drug changes
Reminder: Submit drug prior authorization electronically
Drug prior authorization can be submitted electronically
Upcoming medical and pharmacy drug changes
Upcoming medical and pharmacy drug changes
GLP-1 Weight-loss drug coverage changes coming for Medicaid members
Effective Jan. 1, 2026, coverage and criteria of GLP-1 weight-loss drugs Saxenda, Wegovy and Zepbound will become more restrictive for all Michigan Medicaid members.
Commercial drug coverage changes coming for Tysabri and Revlimid
Commercial drug coverage changes coming for Tysabri and Revlimid
Dalvance® to be removed from coverage in place of generic
Effective. Feb. 4, 2026, Dalvance® will be removed from medical drug coverage for commercial group and individual members and replaced with its generic, Dalbavancin.